For the two $25,000 scholarships, forty kids with cystic fibrosis (CF) are competing based on their academic achievement, inventiveness, and extracurricular activities. The scholarship program this year commemorates 30 years of AbbVie's (NYSE:ABBV) dedication to CF kids seeking higher education.
The beginning of the two-week public voting session for the 2022 Thriving Undergraduate and Graduate Scholarships was announced by AbbVie today. Following this voting session, two deserving students with cystic fibrosis (CF), a hereditary chronic condition that affects the lungs and digestive system, will receive scholarships worth $25,000 each.
The public is invited to visit the official AbbVie CF Scholarship website starting today and continuing through September 28 at 10 a.m. Central Time to read the essays and see the innovative presentations of this year's top 40 students. The 2022 Thriving Undergraduate and Graduate Scholarship winners will then be decided by popular vote. During the two-week public voting session, votes may be made online or by text message by sending the scholar's unique ID code to "58185."
Beyond receiving the AbbVie CF Scholarship, Melissa W., a 2021 Thriving Graduate Student, expressed her gratitude for having the opportunity to share her cystic fibrosis story with the world. "With the support of this scholarship, I am eager to continue utilizing my voice to inspire and advocate for others as I pursue my degree in human resources management."
AbbVie chose 40 undergraduate and graduate CF-affected students earlier this year to receive a $3,000 grant to be used throughout the 2022–2023 academic year. Their outstanding academic performance, creativity, and extracurricular activity all played a part in the award. The opportunity to become a "2022 Thriving Undergraduate or Graduate Student" and receive an additional $22,000 in scholarship money for their higher education is now available to these 40 students. The two winners will be chosen based on the aggregate points each scholar received from the AbbVie judging panel when they assessed the student essays and creative presentations, as well as the total number of valid votes given by the public.
According to John Duffey, vice president of U.S. Specialty at AbbVie, "The 30th anniversary of the AbbVie CF Scholarship program recognizes the community of students we have been able to support throughout the years in their efforts to seek higher education."
"The top 40 beneficiaries for 2022 are beyond deserving and have inspired us all with their remarkable stories and intentions to accomplish their goals despite living with CF," said one of the judges. Beginning in early November, AbbVie will reveal the 2022 Thriving Undergraduate and Graduate Students.
The Future of Abbvie Stock
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV), one of the stocks. Therefore, it could be a good idea to evaluate some of the variables that could impact the stock's performance in the near future.
In contrast to the -3.1% move in the Zacks S&P 500 composite during the past month, shares of this drugmaker have returned -1.1%. AbbVie's sector, Zacks Large Cap Pharmaceuticals, has experienced a 2.3% decline during this time. Where might the stock be heading in the near future is now the crucial question.
There are always some underlying truths that ultimately predominate the buy-and-hold decision-making, even when media releases or speculations about a significant change in a company's business prospects typically make its stock "trending" and result in an immediate price movement.
Abbvie stock projections for the current quarter
AbbVie (NYSE:ABBV) is anticipated to report earnings of $3.59 per share for the upcoming quarter, representing an increase of +7.8% from the same period last year. Over the previous 30 days, the Zacks Consensus Estimate stayed constant.
The consensus profit forecast of $13.90 for the current fiscal year indicates an increase of +9.5% over the previous year. This estimate has not changed over the past 30 days.
The consensus profits estimate of $11.80 for the upcoming fiscal year is a change of -15.1% from what AbbVie is anticipated to report in the prior year. The estimate hasn't altered in the past month.
Abbvie Revenue Projection
Although earnings growth is likely the best sign of a firm's financial health, if a company is unable to raise its revenues, nothing happens as such. After all, it's practically hard for a business to sustainably improve earnings without also expanding revenues. Therefore, it's crucial to understand a company's potential for revenue growth.
The consensus sales forecast of $15.06 billion for the upcoming quarter for AbbVie indicates a +5% change from the same period last year. Estimates of $59.23 billion and $55.92 billion for the current and following fiscal years, respectively, show changes of +5.4% and -5.6%.
Earlier Reported Outcomes
In the most recent reported quarter, AbbVie (NYSE:ABBV) recorded revenues of $14.58 billion, an increase of 4.5% over the same period in the previous year. EPS for the same period was $3.37, up from $3.11 in the prior year. The announced revenues are -0.48% lower than the $14.65 billion Zacks Consensus Estimate, which was released earlier. The unexpected EPS was +1.81%.
In each of the previous four quarters, the company exceeded consensus EPS projections. In any of the previous four quarters, the company was unable to surpass consensus revenue projections. This week, AbbVie Inc. stock is up.
Abbvie Stock Has a SAFE Rating
AbbVie stock has recently seen positive market sentiment overall. The InvestorsObserver Stock Sentiment Indicator rates ABBV as Bullish. According to the most recent "DividendRank" analysis, AbbVie Inc. (NYSE:ABBV) has been named to the Dividend Channel "S.A.F.E. 25" list, designating a stock with above-average "DividendRank" statistics, including a robust 4.0% yield and a great track record of at least two decades of dividend increase.
AbbVie Inc. is listed as a participant in the iShares S&P 1500 Index ETF (ITOT) and as an underlying holding representing 1.21% of the SPDR S&P Dividend ETF (SDY), which holds ABBV shares worth $269,869,124, according to the ETF Finder at ETF Channel.
Featured Image- Megapixl @ Rimidolove
